Coronavirus disease 2019 vaccination in patients with autoimmune diseases

Y. Guan, F. Mu, W. Zhang, Y. Qiao, C. Wang, S. Chen, G. Guo, J. Wang
{"title":"Coronavirus disease 2019 vaccination in patients with autoimmune diseases","authors":"Y. Guan, F. Mu, W. Zhang, Y. Qiao, C. Wang, S. Chen, G. Guo, J. Wang","doi":"10.3760/cma.j.cn114015-20210702-00740","DOIUrl":null,"url":null,"abstract":"Benifits outweigh the risks for patients with autoimmune disease (AID) in remission period to be vaccinated with coronavirus disease 2019 (COVID-19) vaccines. The mRNA vaccines, inactivated vaccines, and recombinant protein subunit vaccines are safe for AID patients, whereas the safety of recombinant adenovirus vector-based vaccines is still uncertain. Some drugs for the treatment of AID may reduce the immune response of the body to the COVID-19 vaccines and affect the immune efficacy of the vaccine, which may be related to the timing of vaccination. Based on several published relevant guidelines and recommendations for the COVID-19 vaccines in AID patients, this article elaborates on vaccination problems to be paid attention to in patients with AID treated with different drugs. Copyright © 2021 by the Chinese Medical Association.","PeriodicalId":7863,"journal":{"name":"药物不良反应杂志","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"药物不良反应杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn114015-20210702-00740","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Benifits outweigh the risks for patients with autoimmune disease (AID) in remission period to be vaccinated with coronavirus disease 2019 (COVID-19) vaccines. The mRNA vaccines, inactivated vaccines, and recombinant protein subunit vaccines are safe for AID patients, whereas the safety of recombinant adenovirus vector-based vaccines is still uncertain. Some drugs for the treatment of AID may reduce the immune response of the body to the COVID-19 vaccines and affect the immune efficacy of the vaccine, which may be related to the timing of vaccination. Based on several published relevant guidelines and recommendations for the COVID-19 vaccines in AID patients, this article elaborates on vaccination problems to be paid attention to in patients with AID treated with different drugs. Copyright © 2021 by the Chinese Medical Association.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
自身免疫性疾病患者的2019冠状病毒病疫苗接种
处于缓解期的自身免疫性疾病(AID)患者接种2019冠状病毒病(COVID-19)疫苗的益处大于风险。mRNA疫苗、灭活疫苗和重组蛋白亚单位疫苗对艾滋病患者是安全的,而重组腺病毒载体疫苗的安全性仍不确定。一些用于治疗艾滋病的药物可能会降低机体对COVID-19疫苗的免疫反应,影响疫苗的免疫功效,这可能与接种时间有关。本文根据已发表的多份艾滋病患者COVID-19疫苗的相关指南和建议,阐述了不同药物治疗艾滋病患者应注意的疫苗接种问题。中华医学会版权所有©2021。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
药物不良反应杂志
药物不良反应杂志 Medicine-Pharmacology (medical)
CiteScore
0.20
自引率
0.00%
发文量
3395
期刊介绍:
期刊最新文献
Coronavirus disease 2019 vaccination in patients with autoimmune diseases Coronavirus disease 2019 vaccination in patients with chronic kidney diseases Thoughts on vaccine hesitancy in the context of coronavirus disease 2019 epidemic Coronavirus disease 2019 vaccination in cancer patients Research progress on effectiveness and safety of approved coronavirus disease 2019 vaccines
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1